STRUCTURAL BIOINFORMATICS INC. ELECTS
MAHENDRA G. SHAH, PH.D. TO SBI BOARD OF DIRECTORS

Business Editors and Health Writers

SAN DIEGO, CA - January 21, 1997 (Business Wire) - Structural Bioinformatics Inc. (SBI), San Diego, developer of leading edge supercomputer-based technology for rapid conversion of novel gene sequence information into protein structural information and drug lead compounds, announced that Dr. Mahendra G. Shah has been elected to the Structural Bioinformatics' Board of Directors.

Dr. Shah is Vice President of EJ Financial Enterprises, Chicago, where he has principal responsibilities for assessing new health care opportunities, negotiating and structuring deals, and providing strategic assistance to the group's active international portfolio of companies. Dr. Shah is on the Board of Introgen Therapeutics, Inc., Horizon Pharmaceutical Corporation, Aegis Technology, Inc., Murty Pharmaceuticals, Inc., Vitamed Laboratories, Inc., Editha Scientific, Inc., and Criticare Laboratories. Dr. Shah, who has approximately 25 years of experience in the health care, was the Senior Director of New Business Development for Fujisawa USA. Prior to this, he held various scientific and management positions with Bristol Myers-Squibb and Schering-Plough.

"We're delighted that Dr. Shah has accepted this appointment. His many years of experience in the health care field and his natural business acumen for leading start-up companies to success will contribute greatly to SBI's success as the leading structural bioinformatics company", said Dr. Edward T. Maggio, President and CEO of SBI.

Structural Bioinformatics has developed a supercomputational operating system making possible the immediate and practical use of genomic (gene sequence) data in a broad range of structure-based drug discovery and design processes leading to the rapid design and identification of small molecule lead compounds. SBI is building corporate partnerships with pharmaceutical companies, gene discovery companies, and combinatorial chemistry companies ranging from broad technology collaborations to assistance with specific drug targets or target groups.